FDA approves first drug for neurotrophic keratitis

FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye disease. Oxervate is the first drug approved in the U.S. for the indication, according to the agency.

A spokesperson said Dompe will launch Oxervate in the U.S. by early 2019 and that the price has not yet been determined...